Germans Want GSK Pandemrix Swine Flu Vaccine Scrapped - What Are The British Getting?

THE GERMAN Medical Association (BAK) has advised against giving young children and pregnant women the new swine flu vaccine Pandemrix from GlaxoSmithKline, containing an immune system-stimulating compound. Many leading paediatricians, virus experts and medical organisations are concerned about the “adjuvant” booster compound it contains and oppose its use in high-risk groups until more long-term data are collected. Germany’s DAK opposes the vaccine’s use in risk-groups saying that, since the risks of swine flu are lower than initially feared, it would be unwise to rely exclusively on new vaccines containing adjuvants.

Derek Scally in Berlin, Irish Times

Related Links:
* Pregnant Women In Britain Given Untested Pandemrix Swine Flu Vaccine
Thomas Moore, Sky News
* GSK’s Pandemrix Swine Flu Vaccine - Pandora's Box Release
Lara, Health Advocate
* Child Vaccines Overload - Swine Flu Shot Untested
Beezy Marsh, Daily Mail

75% Of Finns Say No To Swine Flu Vaccine

In Finland at least three big media outlets, Ilta-Sanomat, MTV3 and Helsingin Sanomat, have held polls asking the Finnish people if they are going to take the swine flu vaccine. 75% said No.

Information Release,

A New Strain Of Swine Flu Or Change In Surveillance?

The Australian Government recently prioritized a vaccine for community use against a new strain of influenza. This preventative action is notable as there has been little evidence in the community that suggests this influenza strain is more virulent than other new strains which occur regularly. An examination of evidence provided by the Western Australian Health Department regarding deaths to swine influenza Type A H1N1 prompts us to ask if it is possible that a change in the surveillance of influenza in 2009 has resulted in the creation of hysteria over a new strain of influenza? These changes in surveillance mean that even though influenza Type A H1N1 has been prevalent in previous years there is no data on the number of deaths associated with this strain in previous years because it hasn’t been monitored.

Judy Wilyman (BSc,MSc,Dip.Ed), PhD Candidate, Murdoch University

Related Links:
* Coercive And Mandatory Immunisation
Judy Wilyman (BSc,MSc,Dip.Ed), PhD Candidate, Murdoch University
* An Analysis of Whooping Cough Incidence
Judy Wilyman (BSc,MSc,Dip.Ed), PhD Candidate, Murdoch University
* Childhood Vaccination - Informed Decisions Brochure
Judy Wilyman (BSc,MSc,Dip.Ed), Associate Professor Peter Dingle

Boston Community Unites To Defend Against Deadly BioTerror Lab

A new lab for studying dangerous disease has raised worries among residents near BU

Boston University’s (BU) recently-constructed Biosafety Level-4 (BSL-4) laboratory has raised concerns among local residents and academics who question the new building’s ability to facilitate the safe study of dangerous pathogens that have no known cure. “They are working with pathogens for which there is no known cure, which could potentially be turned into biological weapons,” Vicky Steinitz, co-coordinator of the Greater Boston Committee of the Coalition to Stop the BioTerror Lab, told the Daily. “In theory, these are biodefense labs. But to learn how to cure against these weapons, you essentially have to weaponize them.” Alan Meyers, associate professor of pediatrics at BU’s School of Medicine and primary care pediatrician at Boston Medical Center said: “Clearly the forces that wanted to have this happen did not want to hear the general BU medical community’s dissent,” Meyers told th e Daily. “The voices of opposition are really not welcome.”

Gabrielle Hernandez, The Tufts Daily

No Surprise Here: Pharma’s DC Lobbying Is Up

With the battle over USA health care reform still under way, the industry’s trade group spent almost as much on lobbying during the first nine months of this year as in all of 2008, according to records reviewed by Bloomberg News. The Pharmaceutical Research and Manufacturers of America spent $19.9 million to lobby Congress and federal agencies during the first nine months of 2009, according to disclosure statements filed with the U.S. Senate. By contrast, PhRMA spent $20.2 million in all of 2008. Another shocker: the trade group for health insurers, America’s Health Insurance Plans, also may surpass its 2008 lobbying spending.

Ed Silverman, Pharmalot